Poxel (PXXLF) Stock Price, News & Analysis

Company Overview

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

Key Stats

• Today's Range: $0.25 to $0.25
• 50-Day Range: $0.25 to $0.25
• 52-Week Range: $0.25 to $0.25
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $7.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PXXLF Stock Analysis - Frequently Asked Questions

How have PXXLF shares performed this year?

Poxel's stock was trading at $0.25 at the start of the year. Since then, PXXLF shares have increased by 0.0% and is now trading at $0.25.
View the best growth stocks for 2025 here.

How do I buy shares of Poxel?

Shares of PXXLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 5/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Private households
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:PXXLF
• CIK: N/A
• Web: www.poxel.com
• Phone: 33-4-37-37-20-10
• Fax: 043-770-8815
• Employees: 15
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $710,000.00
• Price / Sales: 10.19
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 28,953,000
• Free Float: N/A
• Market Cap: $7.24 million
• Optionable: Not Optionable
• Beta: 0.53